336 related articles for article (PubMed ID: 15105519)
1. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
[TBL] [Abstract][Full Text] [Related]
2. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
Yan X; Hu HT; Liu S; Sun YH; Gao X
Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
[TBL] [Abstract][Full Text] [Related]
5. Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
Ganesalingam J; Pizzo E; Morris S; Sunderland T; Ames D; Lobotesis K
Stroke; 2015 Sep; 46(9):2591-8. PubMed ID: 26251241
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
Leppert MH; Campbell JD; Simpson JR; Burke JF
Stroke; 2015 Jul; 46(7):1870-6. PubMed ID: 26012639
[TBL] [Abstract][Full Text] [Related]
7. Potential gains and costs from increasing access to thrombolysis for acute ischemic stroke patients in New Zealand hospitals.
Te Ao B; Brown P; Fink J; Vivian M; Feigin V
Int J Stroke; 2015 Aug; 10(6):903-10. PubMed ID: 24206567
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.
Pan Y; Chen Q; Zhao X; Liao X; Wang C; Du W; Liu G; Liu L; Wang C; Wang Y; Wang Y;
PLoS One; 2014; 9(10):e110525. PubMed ID: 25329637
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
[TBL] [Abstract][Full Text] [Related]
12. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of thrombolytic treatment for stroke.
Mar J; Begiristain JM; Arrazola A
Cerebrovasc Dis; 2005; 20(3):193-200. PubMed ID: 16088115
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.
Kaboré N; Marnat G; Rouanet F; Barreau X; Verpillot E; Menegon P; Maachi I; Berge J; Sibon I; Bénard A
Rev Neurol (Paris); 2019 Apr; 175(4):252-260. PubMed ID: 30642680
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.
Tseng MC; Chang KC
Acta Neurol Taiwan; 2004 Sep; 13(3):149-55. PubMed ID: 15508942
[TBL] [Abstract][Full Text] [Related]
16. Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.
Chiumente M; Gianino MM; Minniti D; Mattei TJ; Spass B; Kamal KM; Zimmerman DE; Muca A; Luda E
Int J Stroke; 2015 Aug; 10(6):849-55. PubMed ID: 25854294
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
Tung CE; Win SS; Lansberg MG
Stroke; 2011 Aug; 42(8):2257-62. PubMed ID: 21719767
[TBL] [Abstract][Full Text] [Related]
18. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
Jones ML; Holmes M
Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
[TBL] [Abstract][Full Text] [Related]
19. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke.
Moodie ML; Carter R; Mihalopoulos C; Thrift AG; Chambers BR; Donnan GA; Dewey HM
Stroke; 2004 May; 35(5):1041-6. PubMed ID: 15031457
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
